Description

Temporal lobe epilepsy is the most common form of drug-refractory epilepsy, and affects millions of individuals worldwide. Hallmarks of TLE are the presence of astrogliosis, activated microglia, neuroinflammation and a substantial neuronal loss in hippocampus. Recently, interests in the ghrelin system are on the rise, as ghrelin receptor (ghrelin-R) agonists were anticonvulsive in acute epilepsy models. Besides this, ghrelin exerts anti-inflammatory actions and was demonstrated to be neuroprotective, therefore ghrelin-R modulation has the potential to be a disease-modifying agent. Antiepileptogenic properties of ghrelin-R modulation and the downstream mechanisms-of-action will be investigated by using ghrelin-R knock-out mice and by two potent ghrelin-R agonists, macimorelin and ibutamoren in clinically relevant chronic epilepsy models. The D1R-kindling model will unveil the importance of hippocampal G-protein coupled receptor heterodimeric interactions of the ghrelin-R with the D1 receptor in epilepsy, and the dissection of various pathways via hippocampal cell cultures will aid in explaining observations in in vivo experiments.
The anticipated outcomes of this project could have serious consequences for the development of novel, more effective therapeutic strategies for epilepsy.
Short titleFWO SB mandate
AcronymFWOSB40
StatusActive
Effective start/end date1/02/1831/01/20

    Flemish discipline codes

  • Laboratory medicine not elsewhere classified

    Research areas

  • medical science, epilepsy

ID: 36166665